Andrew Miller

Dr. Miller is a highly accomplished biopharmaceutical executive with expertise in neuroscience research and development and corporate strategy, most recently serving as Founder and President of Research and Development (R&D) at Karuna Therapeutics, a biopharmaceutical company developing treatments for psychiatric and neurological conditions that was acquired earlier this year by Bristol Myers Squibb (BMS). Dr. Miller is the lead inventor of KarXT (xanomeline-trospium), the Company’s lead pipeline asset that is currently under review by the U.S. Food and Drug Administration for the treatment of schizophrenia. Since founding the Company, he served as President of Research and Development, Chief Operating Officer, Chief Executive Officer, and as a member of Karuna’s board of directors. Over that period, Dr. Miller led discovery, early through late-stage clinical development, manufacturing, and corporate development, including raising approximately $2B in private and public investor capital prior to the Company’s acquisition. Dr. Miller currently serves on the board of directors of Progentos Therapeutics and Entrega. Dr. Miller previously held leadership positions at PureTech Health, Tal Medical, and Entrega Inc. He received his B.S. in Chemical Engineering from the University of Illinois, and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology where he was a Presidential Fellow.